Molecular testing informs treatment options; LFNZ’s view is that patients in NZ should be tested for the following biomarkers at the time of diagnosis (and informed of the results irrespective of the reimbursement status of treatment options); ALK, EGFR, KRAS, RET, MET, ROS1, BRAF, HER2, NTRK1 And PD-L1.